Atovaquone proguanil indications and usage: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Atovaquone proguanil}} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MALARONE (ATOVAQUONE AND PROGUANIL...") |
No edit summary |
||
| (5 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Indications And Usage== | |||
===Prevention of Malaria=== | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MALARONE (ATOVAQUONE AND PROGUANIL HYDROCHLORIDE) TABLET, FILM COATED [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fc22e8d8-3bfb-4f70-a599-dd81262a4887 | publisher = | date = | accessdate = }}</ref> | Atovaquone proguanil® is indicated for the prophylaxis of Plasmodium falciparum malaria, including in areas where chloroquine resistance has been reported. | ||
===Treatment of Malaria=== | |||
Atovaquone proguanil is indicated for the treatment of acute, uncomplicated P. falciparum malaria. Atovaquone proguanil has been shown to be effective in regions where the drugs [[chloroquine]], [[halofantrine]], [[mefloquine]], and [[amodiaquine]] may have unacceptable failure rates, presumably due to drug resistance.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MALARONE (ATOVAQUONE AND PROGUANIL HYDROCHLORIDE) TABLET, FILM COATED [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fc22e8d8-3bfb-4f70-a599-dd81262a4887 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 05:27, 7 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Indications And Usage
Prevention of Malaria
Atovaquone proguanil® is indicated for the prophylaxis of Plasmodium falciparum malaria, including in areas where chloroquine resistance has been reported.
Treatment of Malaria
Atovaquone proguanil is indicated for the treatment of acute, uncomplicated P. falciparum malaria. Atovaquone proguanil has been shown to be effective in regions where the drugs chloroquine, halofantrine, mefloquine, and amodiaquine may have unacceptable failure rates, presumably due to drug resistance.[1]
References
Adapted from the FDA Package Insert.